期刊
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
卷 24, 期 10, 页码 1317-1320出版社
WILEY
DOI: 10.1111/1756-185X.14194
关键词
aging; cancer; COVID-19; osteoarthritis; rheumatoid arthritis
类别
IL-6 is a key soluble factor involved in immune regulation and inflammation, with targeted therapies showing promise in treating diseases like rheumatoid arthritis and COVID-19. Inhibiting the IL-6 pathway may have a broad impact on inflammatory conditions in elderly individuals, including osteoarthritis and cancer.
Interleukin (IL)-6 is a soluble factor secreted by T lymphocytes, involved in antibody generation by B lymphocytes. The IL-6 pathway has risen as a pivotal pathway implicated in immune regulation and dysregulation in various rheumatic diseases. Nonetheless, elevated IL-6 levels can also play a role in cancer. Targeting the IL-6 pathway has led to innovative therapeutic approaches for rheumatic diseases and for COVID-19, particularly in the elderly. Indeed, tocilizumab, an agent targeting IL-6, has recently amassed significant attention as a promising univocal agent for different conditions. In this viewpoint, we sought to recall and describe the common pathway among osteoarthritis, rheumatoid arthritis, and cancer, suggesting that anti-IL-6 may be considered a jack-of-all-trades against inflammaging in the elderly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据